UnknownNot Applicable

Impact of Low Muscle Mass in HNC Treated With Immunotherapy

Spain120 participantsStarted 2021-01-20

Plain-language summary

The purpose of the study is to evaluate the baseline muscle mass as a predictive biomarker of treatment response in patients with recurrence or metastatic squamous cell carcinoma of the head and the neck (SCCHN) treated with immune checkpoint inhibitors (ICI)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients diagnosed with recurrence or metastatic SCCHN treated with antiPDL1, antiPD1 or antiCTLA-4 drugs, alone or in combination within our institution. * Patients who have previously signed informed consent. * Patients with measurable tumor lesions. Exclusion Criteria: * Patients with non-measurable lesions. * Patients who do not sign the informed consent. * Patients not treated with immunotherapy. * Patients in a double-blind trial in whom the assigned branch is not known.

What they're measuring

Evaluate the baseline muscle mass as a predictive biomarker of treatment response in patients with recurrence or metastatic squamous cell carcinoma of the head and the neck (SCCHN) treated with immune checkpoint inhibitors (ICI)

Timeframe: at baseline

Trial details

NCT IDNCT04721184

SponsorInstitut Català d'Oncologia

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-11

Contact for this trial

Lorena Arribas

932607751 larribas@iconcologia.net

View on ClinicalTrials.gov More Head and Neck Small Cell Carcinoma trials